Bold
Investors
ASX
Latest News
ASX Announcements
Companies
Home
ASX Announcements
NXN Announcements
FDA feedback derisks US approval…
NXN
NEXSEN LIMITED
Market sensitive
FDA feedback derisks US approval pathway for StrepSure
Date and time
23 March 2026 at 7:26 pm
Announcement type
Company Update
Show details
Hide details
Category
Other
Report codes
11001
Sector
Health Care
Industry group
Pharmaceuticals, Biotechnology & Life Sciences
View on ASX
Open original PDF
NXN announcement history
Recent NXN announcements
Quarterly Report - Q4 FY26
Launch of Hong Kong facility & pipeline expansion
Global Healthcare CEO Joins Nexsen Advisory Board
$1.5m non-dilutive ARC funding for manufacturing
Becoming a substantial holder
Nexsen secures first hospital partner in Asia